Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Firebrick Pharma Limited ( (AU:FRE) ) is now available.
Firebrick Pharma Limited successfully defended its Nasodine Nasal Spray patent in Singapore against Medzolution Pte, which was selling an infringing product. This defense strengthens Firebrick’s market position as it launches Nasodine in Singapore through a partnership with Guardian pharmacy group, emphasizing the product’s innovation and patent protection.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical company focused on developing and commercializing innovative formulations and uses of povidone-iodine (PVP-I). The company has introduced products like Nasodine Nasal Spray and is expanding its market presence in the United States and Singapore.
YTD Price Performance: 3.33%
Average Trading Volume: 63,195
Technical Sentiment Consensus Rating: Hold
See more insights into FRE stock on TipRanks’ Stock Analysis page.
